News & Updates
Filter by Specialty:
No benefit from adding interferon beta-1a to remdesivir in COVID-19
Adding interferon beta-1a to remdesivir did not hasten time to recovery among adults hospitalized with COVID-19, according to results of the phase III ACTT*-3 trial.
No benefit from adding interferon beta-1a to remdesivir in COVID-19
16 Dec 2021Radiographic progression of interstitial lung disease portends long-term mortality risk
Among patients with systemic sclerosis-interstitial lung disease (SSc-ILD), radiographic progression of ILD over time is predictive of elevated long-term mortality, as shown in a study.
Radiographic progression of interstitial lung disease portends long-term mortality risk
14 Dec 2021Is prior allergy a deal-breaker for COVID-19 vacc?
A large prospective, observational study has suggested that while individuals with a history of high-risk allergy may have an increased risk of allergic reactions following receipt of a messenger RNA (mRNA) COVID-19 vaccine, they are still able to receive both vaccine doses.
Is prior allergy a deal-breaker for COVID-19 vacc?
13 Dec 2021Carbocisteine, gingko leaf extract boost milrinone’s efficacy against COPD complicated by PAH
The combination of carbocisteine, gingko leaf extract, and milrinone yields significant clinical improvement in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), a recent study has found. In turn, this treatment regimen also leads to better patient quality of life.
Carbocisteine, gingko leaf extract boost milrinone’s efficacy against COPD complicated by PAH
09 Dec 2021Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.
Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
08 Dec 2021AECOPD outcomes unaltered with short-course nonmacrolide therapy
Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.